Published on 17 May 2022 on Zacks via Yahoo Finance
Kamada (KMDA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -233.33%. A quarter ago, it was expected that this biopharmaceutical would post a loss of $0.01 per share when it actually produced a loss of $0.10, delivering a surprise of -900%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.